GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 3: Epidemiological distribution of Mayaro virus by Pezzi, L. et al.
HAL Id: pasteur-02305886
https://hal-pasteur.archives-ouvertes.fr/pasteur-02305886
Submitted on 4 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives| 4.0
International License
GloPID-R report on chikungunya, o’nyong-nyong and
Mayaro virus, part 3: Epidemiological distribution of
Mayaro virus
L. Pezzi, A.J. Rodriguez-Morales, C.B. Reusken, G.S. Ribeiro, A.D. Labeaud,
R. Lourenço-De-Oliveira, P. Brasil, M. Lecuit, Anna-Bella Failloux, P.
Gallian, et al.
To cite this version:
L. Pezzi, A.J. Rodriguez-Morales, C.B. Reusken, G.S. Ribeiro, A.D. Labeaud, et al.. GloPID-R report
on chikungunya, o’nyong-nyong and Mayaro virus, part 3: Epidemiological distribution of Mayaro
virus. Antiviral Research, Elsevier Masson, 2019, 172, pp.104610. ￿10.1016/j.antiviral.2019.104610￿.
￿pasteur-02305886￿
Contents lists available at ScienceDirect
Antiviral Research
journal homepage: www.elsevier.com/locate/antiviral
GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 3:
Epidemiological distribution of Mayaro virus
L. Pezzia,b,∗, A.J. Rodriguez-Moralesc, C.B. Reuskend,e, G.S. Ribeirof, A.D. LaBeaudg,
R. Lourenço-de-Oliveirah, P. Brasili, M. Lecuitj, A.B. Faillouxk, P. Gallianl, T. Jaenischm,
F. Simonn, A.M. Siqueirai, M.G. Rosa-Freitash, A. Vega Ruao, S.C. Weaverp, J.F. Drexlerq,r,
N. Vasilakiss, de Lamballerie Xa, on behalf of GloPID-R chikungunya, o'nyong-nyong and Mayaro
virus Working Group (S. Boyert, M. Buschu, M. Diallov, M.S. Diamondw,x,y, M.A. Drebotz,
A. Kohlaa, J. Neytsab, L.F.P. Ngac, M. Riosad, A. Sallv, G. Simmonsae,af)
aUnité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
b EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte, France
c Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnologica de Pereira, Pereira, Colombia
d Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
e Department Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands
fGonçalo Moniz Institute, Oswaldo Cruz Foundation, Federal University of Bahia, Salvador, Brazil
g Department of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, USA
h Instituto Oswaldo Cruz-Fiocruz, Laboratório de Mosquitos Transmissores de Hematozoários, Rio de Janeiro, Brazil
i Instituto Nacional de Infectologia Evandro Chagas - Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
j Institut Pasteur, Biology of Infection Unit, Inserm U1117, Paris Descartes University, Departement of Infectious Diseases and Tropical Medicine, Necker-Enfants Malades
University Hospital, APHP, IHU Imagine, Paris, France
k Department of Virology, Institut Pasteur, Arboviruses and Insect Vectors Unit, Paris, France
l Établissement Français du Sang Alpes Méditerranée, Marseille, France
m Section Clinical Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany
n Laveran Military Teaching Hospital, Marseille, France
o Laboratory of Vector Control Research, Environment and Health Unit, Institut Pasteur de la Guadeloupe, Guadeloupe
p Institute for Human Infections and Immunity and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, USA
q Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Institute of Virology, 10117,
Berlin, Germany
rGerman Centre for Infection Research (DZIF), Germany
sDepartment of Pathology, Institute of Human Infection and Immunity, University of Texas Medical Branch, Galveston, USA
tMedical Entomology Platform, Institut Pasteur du Cambodge, Phnom Penh, Cambodia
u Blood Systems Research Institute, San Francisco, Department of Laboratory Medicine, University of California, San Francisco, USA
vUnité d'Entomologie Médicale, Institut Pasteur de Dakar, Dakar, Senegal
w Department of Medicine, The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine,
St. Louis, USA
x Department of Molecular Microbiology, The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School
of Medicine, St. Louis, USA
yDepartment of Pathology and Immunology, The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University
School of Medicine, St. Louis, USA
z Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
aaMRC-University of Glasgow Centre for Virus Research, Glasgow, UK
ab KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium
ac Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore
adDivision of Emerging and Transfusion Transmitted Diseases, Laboratory of Emerging Pathogens, Office of Blood Research and Review, Center for Biologics Evaluation and
Research, U.S. Food and Drug Administration, Silver Spring, USA
ae Blood Systems Research Institute, San Francisco, USA
afDepartment of Pathology and Laboratory Medicine, University of California, San Francisco, San Francisco, USA
https://doi.org/10.1016/j.antiviral.2019.104610
Received 8 September 2019; Accepted 17 September 2019
∗ Corresponding author. Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France.
E-mail address: laura.pezzi3@studio.unibo.it (L. Pezzi).
Antiviral Research 172 (2019) 104610
Available online 20 September 2019
0166-3542/ © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
1. Introduction
Mayaro virus (MAYV) is a mosquito-borne alphavirus (family
Togaviridae), transmitted mainly by Haemagogus species in the
American continent. The first MAYV strains were isolated from the
blood of infected, symptomatic humans in Trinidad and Tobago in 1954
(Anderson et al., 1957). Since then, MAYV was repeatedly detected in
humans and mosquito vectors in Central and Southern America
(Mackay and Arden, 2016; Acosta-Ampudia et al., 2018). Two unique
reports from Haiti raises the issue of circulation in the Caribbean and
requires further confirmatory investigations (Lednicky et al., 2016;
White et al., 2014). MAYV is transmitted by Haemagogus species in an
enzootic cycle using non-human primates (NHPs) as the main amplifi-
cation and maintenance hosts, and humans becoming sporadically in-
fected when venturing in or nearby forest habitats. Currently, three
MAYV genotypes have been described (namely: D, L and N).
MAYV shares with other arboviruses, in particular the related chi-
kungunya virus (CHIKV), a clinical presentation typically characterized
by fever, headache and rash during the acute case, together with a
polyarthralgia that can persist for months or even years (Mackay and
Arden, 2016; Hassing et al., 2010; Halsey et al., 2013; Thiberville et al.,
2013; Heath et al., 2018; Taylor et al., 2005). This makes accurate di-
agnosis based on clinical presentation difficult and it is expected that
cases of MAYV infection are being misdiagnosed and/or underreported
because of the massive circulation of CHIKV (or even dengue virus
(DENV), Zika virus (ZIKV) and oropouche virus (OROV)) in the
Americas in recent decades. Laboratory testing is necessary for differ-
ential and confirmed diagnosis. Cross-reactivity between antibodies
against MAYV and those against related alphaviruses such as CHIKV
exist and can lead to a difficult interpretation of serological results
(Paniz-Mondolfi et al., 2016; Pezzi et al., 2019).
2. GloPID-R chikungunya (CHIKV), o'nyong-nyong (ONNV) and
Mayaro virus (MAYV) Working Group
This work has been accomplished by experts of GloPID-R (Global
Research Collaboration for Infectious Disease Preparedness, www.
glopid-r.org) chikungunya (CHIKV), o'nyong-nyong (ONNV) and
Mayaro virus (MAYV) Working Group. The interest of this group is
focused on the natural history, epidemiology and medical management
of infection by these viruses, in order to identify knowledge gaps and to
propose recommendations for direct future investigations and rectifi-
cation measures. Here, the experts of the GloPID-R Working Group
performed an assessment of the available information regarding the
epidemiological distribution of MAYV. This work complements other
previous or ongoing reports of the GloPID-R Working Group on chi-
kungunya, o'nyong-nyong and Mayaro virus epidemiology (submitted
paper, under review), diagnosis (Taylor et al., 2005), ecology (sub-
mitted paper, under review) and clinics.
3. Sources of data
Data from the first virus isolation until December 2018 were col-
lected, including both acute cases in humans (confirmed by RT-PCR
and/or presence of IgM) as well as results of serological studies showing
past infections in humans (presence of IgG).
Data on MAYV infections were obtained from health organizations
and the peer-reviewed literature concerning all the New World countries.
To identify MAYV cases in humans, firstly we consulted different
public health alert systems and websites, including:
World Health Organization (WHO) - ‘Disease outbreak news (DON)’
section
Program for Monitoring Emerging Diseases (ProMED);
European Centre for Disease Prevention and Control (ECDC)
through ‘Communicable disease threats report (CDTR)’;
Institute of health of each American country, through periodic
bulletins on viral infections (when available).
A comprehensive review of literature on PubMED was conducted
using the search terms ‘mayaro virus’ and the name of each American
and Caribbean country. Finally, viral sequences available in GenBank
were checked, in order to assess the countries where MAYV-positive
human samples were collected. The lineage of MAYV strains (D, L or N)
is indicated in Tables 1–5 of Supplementary data according to in-
formation present in GenBank or in articles linked to the viral sequence;
otherwise, it was defined through phylogenetic reconstruction.
In the article and in Supplementary data we reported details about
MAYV detection: number of cases, year, localization and technique(s)
used to confirm the infection. We classified the sources of our data in 6
categories:
Declared outbreaks
Single case reports (mainly about returning travelers)
Surveillance studies, aiming to identify the etiology of acute ill-
nesses confirmed by PCR and/or serology
Serosurveys (to evaluate previous exposure to the virus, confirmed
by serology)
GenBank sequences, present on the database without additional
information on the isolated strains
Annual report from health authorities.
In this report, experts provided a picture of MAYV geographic
spread through Americas; they identified gaps of knowledge and pro-
posed recommendations in order to suggest research priorities in the
field.
4. MAYV distribution
An account of the epidemiological findings about MAYV human
cases is shown below. Further details are presented in Tables 1–5 of
Supplementary data (Central America, Caribbean, Brazil, Peru and rest
of South America).
4.1. Central America
4.1.1. Mexico
4.1.1.1. Surveillance study. The study was performed on patients with
probable diagnosis of DENV in 2001 (Navarrete-Espinosa and Gómez-
Dantés, 2006). 2 cases were found positive with ELISA IgM, one from
northern Mexico (Tamaulipas state), the other from western Mexico
(Veracruz state).
4.1.2. Panama
4.1.2.1. Serosurvey. Serosurvey conducted retrospectively on samples
collected during the construction of canals in Panama and Colombia in
1904–1914 (Srihongse et al., 1973).
4.1.2.2. Surveillance study. During an encephalitis outbreak in 2010, a
household study was performed testing sera for several arboviruses
(Carrera et al., 2018). One case was positive with ELISA IgM in Darien
region (southern Panama).
4.2. Caribbean
4.2.1. Haiti
4.2.1.1. Case report. One MAYV strain isolated in 2014 from a patient
co-infected with CHIKV living in rural Haiti (White et al., 2014).
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4.2.1.2. Case report. Acute case confirmed in 2015 by virus isolation in
a patient living in the western part of Haiti (Lednicky et al., 2016).
4.2.1.3. Outbreak (NOT CONFIRMED). Febrile undiagnosed fever
suspected of being caused by MAYV in 2018 according to clinical
presentation, not supported by biological evidence (ProMED:
20180909.6018117).
4.2.2. Trinidad and Tobago
4.2.2.1. Outbreak. First isolation of MAYV during an outbreak of febrile
illness in 1954 (Anderson et al., 1957).
4.2.2.2. GenBank sequence (no additional information). 2 MAYV strains
isolated in 1957, both belonging to genotype D. GenBank accession
numbers available in Table 2-Supplementary data.
4.3. Brazil
4.3.1. Outbreak
A MAYV outbreak was detected in Pará state, northern Brazil,
among forest workers (Causey and Maroja, 1957). 6 MAYV strains were
isolated.
4.3.2. Serosurvey
Antibodies against MAYV were detected in sera from Indians living
in the Amazon Basin in Mato Grosso state when tested with HI test in
1963–1964 (Neel et al., 1968).
4.3.3. Serosurvey
Sera from military troops in different areas of the country were
tested by HI and VNT in 1964 (Niederman et al., 1967). 1% of samples
was positive for antibodies against MAYV.
4.3.4. Serosurvey
The survey was performed on sera collected from tribes living in the
Amazon Basin, Brazil (Black et al., 1974). Sera were tested by HI test,
with 42% of positive rate.
4.3.5. GenBank sequence (no additional information)
Two MAYV strains isolated in 1970, both belonging to genotype D.
GenBank accession numbers available in Table 3- Supplementary data.
4.3.6. Outbreak
MAYV outbreak was detected in a small village in Pará state,
northern Brazil, in 1977–1978 (Pinheiro et al., 1981; da Rosa et al.,
1981). It was estimated that 20% of the 4000 inhabitants were infected.
4.3.7. GenBank sequence (no additional information)
3 MAYV strains isolated in 1981, all belonging to genotype D.
GenBank accession numbers available in Table 3- Supplementary data.
4.3.8. GenBank sequence (no additional information)
2 MAYV strains isolated in 1984–1988, both belonging to genotype
L. GenBank accession numbers available in Table 3- Supplementary
data.
4.3.9. GenBank sequence (no additional information)
6 MAYV strains isolated in 1991. 5 belong to genotype D, one to
genotype L. GenBank accession numbers available in Table 3- Supple-
mentary data.
4.3.10. Case report
Three MAYV cases were detected in the state of Mato Grosso,
western Brazil, in 2000 (Coimbra et al., 2007). Samples were tested by
haemagglutination inhibition test (HI).
4.3.11. Case report
The infection was acquired in Acre state, north western Brazil, in
2004 and detected by PCR (Terzian et al., 2015).
4.3.12. Surveillance study
Survey of acute febrile illness in Manaus, northern Brazil, in
2007–2008 (Mourão et al., 2011). 33 cases were confirmed by ELISA
IgM, and in one of them viral genome was detected by PCR.
4.3.13. Outbreak
The outbreak was detected in a very small village in Pará state,
northern Brazil, in 2008 (Azevedo et al., 2009). Cases were diagnosed
by ELISA IgM, and 3 MAYV strains were isolated.
4.3.14. Case report
Imported case- France ex Brazil, 2009 (Receveur et al., 2010). The
patient was infected in Amazonas state, northern Brazil. ELISA detected
presence of IgM in the serum of the patient.
4.3.15. Surveillance study
During a large DENV outbreak in the state of Mato Grosso
(2011–2012), some DENV- samples from acute febrile patients tested
positive by PCR for MAYV (Zuchi et al., 2014).
4.3.16. Surveillance study
Seroprevalence study conducted in Goias state, central Brazil, in
2011–2013. DENV- patients were tested with an enzyme immunoassay
on infected cultured cells (EIA-ICC) (Costa et al., 2017).
4.3.17. Case report
Imported case- The Netherlands ex Brazil, 2013 (Slegers et al.,
2014). After a travel in Pará state, northern Brazil, the patient tested
positive for anti-MAYV IgM and IgG by IFT; the result was confirmed by
VNT.
4.3.18. Case report
One MAYV infection was acquired in Pará state, northern Brazil, in
2014 (Mota et al., 2015). Virus was detected by PCR and isolated.
4.3.19. Surveillance study
Study performed in 2014–2015 on CHIKV- patients from Goias state
(central Brazil), tested for anti-MAYV IgM by ELISA (Brunini et al.,
2017).
4.3.20. Outbreak
MAYV cases were detected in Goias state, central Brazil, in 2015
(ProMED: 20150705.3485723).
4.3.21. GenBank sequence (no additional information)
Virus isolated from human serum in Mato Grosso state, western
Brazil, in 2015, belonging to genotype L. GenBank accession number
available in Table 3- Supplementary data.
4.3.22. Surveillance study
The survey was performed in Mato Grosso state, western Brazil, on
samples from acute febrile patients in 2015–2016 (de Souza Costa et al.,
2019). Cases were detected by PCR.
4.3.23. Surveillance study
The study was conducted in Amazonas state in 2016 testing samples
from patients with acute febrile illness (ProMED: 20161128.4658296).
4.4. Peru
4.4.1. GenBank sequence (no additional information)
8 MAYV strains isolated in 1995, all belonging to genotype D.
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GenBank accession numbers available in Table 4- Supplementary data.
4.4.2. Case report
Cases of MAYV infection reported from different sites in Peru in
1995–1998 (Tesh et al., 1999). 25 cases were detected during ser-
oepidemiological studies on surveillance of acute febrile illnesses; 2
were imported cases (USA ex Peru). MAYV was isolated from 21 pa-
tients, 6 were diagnosed by serology.
4.4.3. GenBank sequence (no additional information)
18 MAYV strains isolated in 1995–2000, all belonging to genotype
D. GenBank accession numbers available in Table 4- Supplementary
data.
4.4.4. Surveillance study
Study performed on samples from febrile patients from different
sites in Peru in 2000–2007 (Forshey et al., 2010). 73 cases were con-
firmed by virus isolation, PCR or IgM seroconversion. 77 additional
cases were classified as presumptive cases (high IgM without ser-
oconversion). 25 MAYV strains were isolated.
4.4.5. GenBank sequence (no additional information)
12 MAYV strains isolated in 2002–2006, all belonging to genotype
D. GenBank accession numbers available in Table 4- Supplementary
data.
4.4.6. GenBank sequence (no additional information)
One MAYV strain isolated in 2010, classified as genotype N.
GenBank accession number available in Table 4- Supplementary data.
4.4.7. Surveillance study
Study performed on sera of febrile patients from different sites of
Peru in 2010–2012 (Halsey et al., 2013). Positive cases were confirmed
by virus isolation and/or PCR and/or ELISA IgM.
4.4.8. GenBank sequence (no additional information)
3 MAYV strains isolated in 2011, all belonging to genotype D.
GenBank accession numbers available in Table 4- Supplementary data.
4.4.9. Case report
Imported case- Switzerland ex Peru, after a travel in northern Peru
in 2011 (Neumayr et al., 2012). Anti-MAYV IgM and IgG were detected
by IF test and diagnosis was confirmed by VNT.
4.4.10. Case report
Imported case- Canada ex Peru, 2018. Viral genome was detected by
PCR (ProMED: 20180518.5804085).
4.4.11. Annual report from health authorities
For the year 2018, Peruvian Health authorities declared 35 MAYV
cases (ProMED: 20190503.6454329).
4.5. Rest of South America
4.5.1. Bolivia
4.5.1.1. Outbreak. An epidemic of jungle fever was detected in eastern
Bolivia in 1955. 192 people got infected; MAYV was responsible for
10–15% of the cases (Schaeffer et al., 1959).
4.5.1.2. Case report. One case of MAYV infection was detected in 1999
and confirmed by serological test (Taylor et al., 2005).
4.5.1.3. Surveillance study. The study was performed in 2000–2007 on
samples from febrile patients from different sites in Bolivia (Forshey
et al., 2010). 24 cases were confirmed by virus isolation, PCR or IgM
seroconversion. 22 additional cases were classified as presumptive
cases (high IgM without seroconversion). 15 MAYV strains were
isolated.
4.5.1.4. GenBank sequence (no additional information). 10 MAYV strains
were isolated in 2002–2006, belonging to genotype D. GenBank
accession numbers available in Table 5- Supplementary data.
4.5.1.5. Case report. Case report- Germany ex Bolivia, 2012 (Theilacker
et al., 2013). The patient probably got infected in Rurrenabaque region
(norther Bolivia). Immunofluorescence test (IFT) and seroneutralization
test were used to diagnose MAYV.
4.5.1.6. Case report. Case report- Germany ex Bolivia, 2014 (Tappe
et al., 2016). Immunofluorescence test (IFT) was positive for IgG anti-
MAYV; result was confirmed by virus neutralization test (VNT).
4.5.2. Colombia
4.5.2.1. Serosurvey. Serosurvey conducted retrospectively on samples
collected during the construction of canals in Panama and Colombia in
1904–1914 (Srihongse et al., 1973).
4.5.2.2. Serosurvey. Seroprevalence study conducted in Santander
state, northern Colombia, in 1959 (Groot et al., 1959). Samples were
tested by HI.
4.5.2.3. Serosurvey. Seroprevalence study performed in different sites
of Colombia in 1966 (Evans et al., 1969). Samples from military recruits
were tested by HI test.
4.5.3. Ecuador
4.5.3.1. Serosurvey. Seroprevalence study performed in south-eastern
Ecuador in 1997 (Izurieta et al., 2011). People native to rainforest had
higher IgG prevalence (46,2%) compared to people from coastal or
mountain areas (2,4%). Samples were tested with ELISA.
4.5.3.2. Surveillance study. Study performed on samples from febrile
patients from western Ecuador (2000–2007) (Forshey et al., 2010). 1
case was confirmed by PCR or IgM seroconversion.
4.5.3.3. Case report. Imported case- Germany ex Ecuador, after a travel
in the jungle in 2014 (Tappe et al., 2016). IF test was positive for both
IgM and IgG anti-MAYV.
4.5.4. French Guiana
4.5.4.1. Case report. A febrile patient tested positive by HI and ELISA
IgM in 1995; the virus was isolated (Talarmin et al., 1998).
4.5.4.2. Serosurvey. Sera from different areas of the country were
tested with HI test in 1995–1996 (Talarmin et al., 1998).
4.5.4.3. GenBank sequence (no additional information). 4 MAYV strains
isolated in 1996–1998, belonging to genotype D. GenBank accession
numbers available in Table 5- Supplementary data.
4.5.4.4. Case report. Imported case- Germany ex French Guiana, 2013.
IgM and IgG anti-MAYV were detected by IF test, and PCR was positive
(Friedrich-Jänicke et al., 2014).
4.5.4.5. Case report. Imported case- France ex French Guiana, after a
travel in the eastern part of the country in 2015. Diagnosis of MAYV
infection was confirmed by PCR and ELISA IgM and IgG (Llagonne-
Barets et al., 2016).
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4.5.5. Suriname
4.5.5.1. Serosurvey. Seroprevalence study conducted on Dutch soldiers
stationed in Suriname in 1984 (Karbaat, 1965).
4.5.5.2. Case report. Imported cases- The Netherlands ex Suriname,
after a travel in the central part of the country, 2008 (Hassing et al.,
2010). IgG were detected by ELISA in both patients, IgM in one patient
only. The infection was confirmed by VNT.
4.5.6. Venezuela
4.5.6.1. Serosurvey. Seroprevalence study performed in northern
Venezuela in 1965 (Jonkers et al., 1965). Samples were tested with
HI and VNT.
4.5.6.2. Case report. Four cases of MAYV infection in Central Venezuela
(2000). Tested by ELISA, 3 patients were positive for IgM anti-MAYV
and all of them had IgG anti-MAYV (ProMED: 20010428.0825).
4.5.6.3. Outbreak. Outbreak detected in Portuguesa state, north
western Venezuela, in 2010 (Auguste et al., 2015). Distribution of
Fig. 1. Acute MAYV cases in humans confirmed by PCR or virus isolation. Countries (in green) where MAYV infections have been suggested based on HI, VNT, PRNT,
IF or ELISA are not classified in the map since cross-reactivity with related alphaviruses may have affected serological assays.
L. Pezzi, et al. Antiviral Research 172 (2019) 104610
5
MAYV cases and MAYV genotypes are presented in Fig. 1 and Fig. 2
5. Discussion
According to the 9th report of the International Committee on
Taxonomy of Viruses (ICTV) (Genus, 2019), MAYV belongs to the
Semliki Forest complex and is related to Una virus, previously con-
sidered a subtype of MAYV (Genus, 2019). MAYV strains have been
classified, on the basis of E1-E2 partial sequences, into three genotypes:
(1) genotype D, largely distributed in South America; (2) genotype L,
supposedly limited to Brazil but recently detected in Haiti, and (3)
genotype N, a newly described clade accounting for just one MAYV
strain isolated in Peru in 2010 (Auguste et al., 2015). We performed a
phylogenetic analysis using 56 MAYV complete genomes and we ob-
served the same subdivision (Fig. 3). Genotype D includes several
clades that segregated by geographic region (Venezuelan, Peruvian,
Bolivian and Brazilian clades); all these isolates are highly conserved
(< 3% nucleotide divergence) but are quite distinct from the other
genotype isolates (5–6% nucleotide divergence with genotype N and
12–13% nucleotide divergence with genotype L). The wide distribution
Fig. 2. Distribution of MAYV genotypes.
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Fig. 3. Phylogenetic analysis of 56 complete MAYV genomes present in GenBank. Neighbor-joining phylogenetic tree was generated with MEGA 6 using Tamura-Nei model
(Gamma distribution) with 1000 bootstrap replication. 10,999 sites were included. All positions containing gaps and missing data were eliminated (complete deletion). The
best substitution model was selected with jModeltest. Tip labels indicate GenBank accession number, strain name, country and year of isolation (when available).
L. Pezzi, et al. Antiviral Research 172 (2019) 104610
7
of genotype D is in contrast to the apparent restriction of genotype L to
Brazil. This may be explained by a sampling bias rather than the ex-
istence of a specific barrier to MAYV dispersal. It would be of interest to
investigate other factors that could be part of genotypic segregation,
such as vector competence, vector distribution or presence of alter-
native amplification hosts. Of note, no clear epidemiological (apart
from geographical distribution), clinical or ecological patterns have
been associated to date with the different genotypes. This obviously
deserves further investigations.
Mayaro virus circulation has been documented only in the
Americas. Data about MAYV cases in humans provide a picture of the
regular spill over events leading to human infections in Central and
South America in the last 65 years. The Amazon region of Brazil pro-
vides the higher number of sporadic cases and epidemics, followed by
Peru and Bolivia. This is not surprising, because these countries share
borders with Brazilian regions where MAYV has been more frequently
detected (Amazonas, Acre and Mato Grosso States). Returning travellers
got infected after stays in several countries such as Ecuador, Suriname
and French Guiana providing evidence of virus circulation (Hassing
et al., 2010; Tappe et al., 2016; Friedrich-Jänicke et al., 2014;
Llagonne-Barets et al., 2016). Data from Central America (Panama,
Costa Rica, Guatemala) are outdated and should be updated to reflect
the recent circulation of the virus in the area. This is valid also for the
Caribbean, especially after a recent report of two cases in Haiti
(Lednicky et al., 2016; White et al., 2014). Overall, seroprevalence and
surveillance studies are urgently needed in both Central and South
America to better assess the actual scale of MAYV diffusion.
Several factors may have contributed to underestimating the actual
prevalence of MAYV infections in humans. First, the widespread cir-
culation of pathogens with an overlapping clinical picture such as
dengue virus (DENV), Zika virus (ZIKV) and CHIKV in the American
continent, makes probable that MAYV infections have commonly been
underreported. Cases of MAYF have been observed during DENV out-
breaks or in patients with DENV-like illness, highlighting the fact that
similar symptoms make several other arboviral diseases indistinguish-
able without laboratory testing. In additions, MAYV RT-PCR diagnosis
remains poorly available and the cross-reactivity observed between
antibodies against MAYV and the closely-related alphaviruses (espe-
cially viruses belonging to Semliki forest complex) is a significant
barrier to specific serological diagnosis.
Second, since epidemiological data on related alphaviruses has been
commonly obtained based on serological tests that also detect to a
various extent antibodies to MAYV, MAYV infections may be more
common than is generally reported (Pezzi et al., 2019). For example, a
seroprevalence study performed in the Amazon Valley of Brazil in
1953–1954 revealed that 18.9% of the samples tested by virus neu-
tralization test were positive for Semliki Forest virus (SFV) (Causey and
Theiler, 1958). Since SFV is confined to Africa and in the same period
MAYV was detected in the Amazon Valley (Causey and Maroja, 1957),
it is possible that such "Semliki Forest-positive" sera actually reflected
exposure to MAYV or related variants. Cross-reactivity with chi-
kungunya virus (CHIKV) was also observed in MAYV infected returning
travellers, which made the diagnosis late and difficult (Hassing et al.,
2010; Friedrich-Jänicke et al., 2014).
According to available data on MAYV distribution, experts identi-
fied several gaps of knowledge and provided adapted recommendations
(Paragraphs 5 and 6). The aim was to identify and suggest research
priorities in the field.
6. Gaps of knowledge
6.1. Entomological and environmental surveillance
Since Haemagogus species are the mosquito transmitter of MAYV in
the American continent, detailing the spatial distribution of the vector
through the continent, especially in border areas between forest and
human habitations, is necessary to inform about regions of increased
risk for human cases. The different aspects relating to entomology and
natural cycle are further developed and discussed in the ongoing report
"entomological aspects and vector control" of the GloPID-R chi-
kungunya, o'nyong-nyong and Mayaro virus Working Group.
6.2. Disease surveillance and epidemiology
In the last 65 years, the circulation of MAYV in central and southern
America has been proven through circumscribed outbreaks, sporadic
serosurveys and case reports of returning infected travellers. The
available information concerning MAYV diffusion is insufficient to as-
sess the actual burden of MAYV in the American continent.
6.3. Laboratory tests for seroprevalence studies
High-performance serological assays are needed to overcome the
issue of antigenic cross-reactivity between member viruses of the
Semliki forest virus serocomplex. In particular, the close phylogenetic
relationship among MAYV and CHIKV explains why MAYV and CHIKV
antibodies commonly cross-react in ELISA or immunofluorescence
testing (Pezzi et al., 2019). Moreover, multiple exposures to various
alphaviruses reduce specificity to all serological assays including ELISA,
HI, CF, and even the gold standard of specificity, seroneutralisation
assys (Pezzi et al., 2019). It is doubtful that adapted and routine ser-
ological tools and interpretation algorithms are currently available to
expedite accurate and large-scale seroepidemiological studies for
MAYV. Better diagnostics are therefore essential to confirm viral
transmission.
6.4. Laboratory algorithm and case definition for clinical care
The current situation is characterized by the absence of a clear la-
boratory algorithm ensuring that MAYV is part of differential diagnosis
in specific cases (e.g. dengue like syndrome with negative DENV la-
boratory testing); there is no discriminatory routine and specialist ser-
ological assays for clinical care; there is no international case definition
for probable and confirmed MAYV cases.
6.5. Diagnosis of acute cases
Very few molecular assays are currently available for MAYV de-
tection. Their performances, as well as their adequacy to detect the
different MAYV lineages, have not been assessed through comparative
studies. No commercial tests exist except for one anti-MAYV ELISA (IgM
and IgG) by EUROIMMUN which has not been clinically evaluated.
Multiplex molecular and serological tests for discrimination of MAYV
and CHIKV in areas of co-circulation are missing, making differential
diagnosis a challenging task. Our information about kinetics of viral
load are limited and derive just from sera (kinetics in different body
fluids have never been investigated). No International Standards (IS)
are available and External Quality Assessment (EQAs) have never been
organized to evaluate laboratories capacity to diagnose MAYV infec-
tion. The different aspects relating to diagnosis of MAYV infection are
further developed and discussed in the report "Biological diagnostics" of
the GloPID-R chikungunya, o'nyong-nyong and Mayaro virus Working
Group (Pezzi et al., 2019).
6.6. Cross-protection
It is unknown whether individuals infected by MAYV or CHIKV are
efficiently protected against secondary infection by the other virus, as
well as by other clinically related alphaviruses. It is also unknown
whether previous infection by MAYV or CHIKV may be responsible for a
potentially more severe infection by the other virus as suggested in the
case of successive infection by different serotypes of DENV. This
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remains to be firmly established from humans or from relevant animal
models.
6.7. Natural history
The natural history of MAYV infection is not accurately character-
ized, as well as the clinical spectrum of the disease, from acute to long-
term sequelae. Few case reports and just one longitudinal study docu-
mented persisting arthralgia post MAYV infections (Hassing et al.,
2010; Halsey et al., 2013; Taylor et al., 2005). Our knowledge on this
subject needs to be increased to determine if a “post-MAYV” syndrome
exists, similar to the “post-CHIKV” syndrome that includes a variety of
long-term (mostly rheumatologic) complications of CHIKV.
6.8. Molecular epidemiology
Convenient genotyping and sequencing techniques are needed to
assist the development of molecular epidemiology studies. Moreover,
clear cut-off of percent identity and criteria allowing a clear classifi-
cation of MAYV strains into genotypes do not exist.
7. Expert recommendations
7.1. Entomological and environmental surveillance
It is necessary to determine the pattern of spatial distribution of
Haemagogus species, to investigate the vector species range involved in
MAYV transmission through field studies and laboratory competence
studies, and to characterize the natural transmission cycle and animal
reservoirs.
7.2. Disease surveillance and epidemiology
Specific efforts are required to better characterize MAYV circulation
and epidemiology at large scale (including clinical epidemiology).
MAYV should be more frequently included in molecular proficiency
panels for febrile illnesses of unknown origin in the Americas, and
seroprevalence studies should be performed. This obviously requires
improved diagnostic assays.
7.3. Laboratory tests for seroprevalence studies
Accurate assays and algorithms allowing to detect IgG antibodies
specific to MAYV and to distinguish them from IgG to CHIKV should be
developed. At this stage, performing seroneutralization tests is essential
for confirmation after performing a screening assay (e.g. ELISA, hae-
magglutination inhibition test or immunofluorescence assay); however,
a proportion of samples remains without clear identification, in parti-
cular in case of co-circulation of related viruses. Clear interpretation
guidelines or new specific assays are required and reference serological
standards are needed (possibly produced from non-human primates
(Pezzi et al., 2019)).
7.4. Laboratory algorithm and case definition for clinical care
Case definitions (for probable and confirmed cases) and a clear di-
agnostic laboratory algorithm should be set-up.
7.5. Diagnosis of acute cases
For diagnosis at the acute stage of the disease, virus co-circulation
requires the development of molecular multiplex tools and specific IgM
assays to differentiate MAYV from related alphaviruses in the Americas.
Viremia kinetics and viral loads in different body fluids should be better
documented, as well as the kinetics of immune response. International
Standards (IS) should be made available, taking into account the MAYV
genetic heterogeneity. Moreover, External Quality Assessments (EQAs)
should be organized in order to assess laboratory capacity of detecting
MAYV with both molecular and serological tools.
7.6. Cross-protection
Cross-protection studies between MAYV and related alphaviruses, in
particular CHIKV, should be implemented. Moreover, it is necessary to
investigate the possible effect of a previous infection by MAYV or
CHIKV on a subsequent infection of MAYV. Both aspects could be
clarified using samples from naturally exposed humans and experi-
mentally infected non-human primates.
7.7. Natural history
Natural history of infection should be better investigated.
Longitudinal studies would prove useful to identify long-term compli-
cations.
7.8. Molecular epidemiology
Genotyping and sequencing protocols should be selected and pro-
posed in order to quickly identify the lineage of circulating viral strains.
The region of the genome that gives the highest information for geno-
typing should be identified and this choice standardized in order to
allow comparisons across laboratories. Cut-off of percent identity
should be standardized to define genotype accurately. Moreover, a
genomic reference database should be made available similar to those
existing for other arboviruses (e.g. the sites of the Virus Variation
Resource (Virus Variation) or the Virus Pathogen Resource (Virus
Pathogen Database and Analysis Resource). It would allow to store
sequence data, gene and protein annotations as well as information
about isolation hosts, country and year.
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